{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:00:06Z","timestamp":1770526806412,"version":"3.49.0"},"reference-count":81,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1111\/ijcp.12979","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T23:56:44Z","timestamp":1501199804000},"page":"e12979","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care"],"prefix":"10.1155","volume":"71","author":[{"given":"Olivier S.","family":"Descamps","sequence":"first","affiliation":[{"name":"Department of Internal Medicine; Centres Hospitaliers Jolimont; Haine Saint-Paul Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fraass","sequence":"additional","affiliation":[{"name":"Amgen GmbH; Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH; Zug Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics; Medical University Graz; Graz Austria"},{"name":"Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology); Medical Faculty Mannheim; University of Heidelberg; Heidelberg Germany"},{"name":"Synlab Academy; Synlab Holding Deutschland GmbH; Mannheim and Augsburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[{"name":"Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP); University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"10.1111\/ijcp.12979-BIB0001|ijcp12979-cit-0001","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe - epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0002|ijcp12979-cit-0002","unstructured":"World Health Organization Cardiovascular diseases (CVDs) 2015 http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/"},{"key":"10.1111\/ijcp.12979-BIB0003|ijcp12979-cit-0003","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0004|ijcp12979-cit-0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1157\/13116658","article-title":"Cardiovascular risk factors. Insights from Framingham Heart Study","volume":"61","author":"O'Donnell","year":"2008","journal-title":"Rev Esp Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0005|ijcp12979-cit-0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12979-BIB0006|ijcp12979-cit-0006","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-2251","article-title":"Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008","volume":"34","author":"Ford","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12979-BIB0007|ijcp12979-cit-0007","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0008|ijcp12979-cit-0008","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1053\/euhj.1999.1402","article-title":"Despite good compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease","volume":"20","author":"Aquilani","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0009|ijcp12979-cit-0009","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJM199304293281701","article-title":"The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia","volume":"328","author":"Hunninghake","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0010|ijcp12979-cit-0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0011|ijcp12979-cit-0011","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archinternmed.2008.552","article-title":"Continuation of statin treatment and all-cause mortality: a population-based cohort study","volume":"169","author":"Shalev","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1111\/ijcp.12979-BIB0012|ijcp12979-cit-0012","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1111\/ijcp.12979-BIB0013|ijcp12979-cit-0013","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2174\/13816128113199990313","article-title":"Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies","volume":"19","author":"Seidah","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1111\/ijcp.12979-BIB0014|ijcp12979-cit-0014","unstructured":"Amgen Inc REPATHA \u00ae (evolocumab) highlights of prescribing information http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.ashx"},{"key":"10.1111\/ijcp.12979-BIB0015|ijcp12979-cit-0015","unstructured":"Amgen Repatha \u00ae (evolocumab) summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003766\/WC500191398.pdf"},{"key":"10.1111\/ijcp.12979-BIB0016|ijcp12979-cit-0016","unstructured":"Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US PRALUENT \u00ae (alirocumab) highlights of prescribing information http:\/\/products.sanofi.us\/praluent\/praluent.pdf"},{"key":"10.1111\/ijcp.12979-BIB0017|ijcp12979-cit-0017","unstructured":"Sanofi-Regeneron Praluent \u00ae (alirocumab) summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003882\/WC500194521.pdf"},{"key":"10.1111\/ijcp.12979-BIB0018|ijcp12979-cit-0018","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/bcp.13066","article-title":"Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia","volume":"82","author":"Gouni-Berthold","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ijcp.12979-BIB0019|ijcp12979-cit-0019","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0020|ijcp12979-cit-0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/apt.17.2.158a","article-title":"Numbers-needed-to-treat analysis","volume":"17","author":"McQueen","year":"2011","journal-title":"Adv Psychiatr Treat"},{"key":"10.1111\/ijcp.12979-BIB0021|ijcp12979-cit-0021","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0022|ijcp12979-cit-0022","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0023|ijcp12979-cit-0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9149(00)00910-3","article-title":"Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering","volume":"86","author":"Pedersen","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0024|ijcp12979-cit-0024","first-page":"5","article-title":"ACC\/AHA cholesterol guideline and implications for healthy people 2020 cardiovascular disease prevention goals","volume":"2016","author":"Egan","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1111\/ijcp.12979-BIB0025|ijcp12979-cit-0025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/ATVBAHA.116.306887","article-title":"Counterpoint: low-density lipoprotein cholesterol targets are not needed in lipid treatment guidelines","volume":"36","author":"Robinson","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/ijcp.12979-BIB0026|ijcp12979-cit-0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0027|ijcp12979-cit-0027","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/ijcp.12979-BIB0028|ijcp12979-cit-0028","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0029|ijcp12979-cit-0029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1111\/ijcp.12979-BIB0030|ijcp12979-cit-0030","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0031|ijcp12979-cit-0031","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1111\/ijcp.12979-BIB0032|ijcp12979-cit-0032","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1111\/ijcp.12979-BIB0033|ijcp12979-cit-0033","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0034|ijcp12979-cit-0034","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0035|ijcp12979-cit-0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300\u00a0mg every 4\u00a0weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1111\/ijcp.12979-BIB0036|ijcp12979-cit-0036","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0037|ijcp12979-cit-0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0038|ijcp12979-cit-0038","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0039|ijcp12979-cit-0039","unstructured":"Raal FJ Hovingh GK Blom D Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the Trial Assessing long-term Use of PCSK9 Inhibition in Subjects with Genetic LDL disorders (TAUSSIG) study"},{"key":"10.1111\/ijcp.12979-BIB0040|ijcp12979-cit-0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12979-BIB0041|ijcp12979-cit-0041","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0042|ijcp12979-cit-0042","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0043|ijcp12979-cit-0043","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12979-BIB0044|ijcp12979-cit-0044","doi-asserted-by":"crossref","first-page":"Abstr 17070","DOI":"10.1161\/circ.132.suppl_3.17070","article-title":"Efficacy and safety of alirocumab: pooled analyses of 1048 individuals with diabetes mellitus from five placebo-controlled phase 3 studies of at least 52\u00a0weeks duration","volume":"132","author":"Ginsberg","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0045|ijcp12979-cit-0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1111\/ijcp.12979-BIB0046|ijcp12979-cit-0046","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.1111\/ijcp.12979-BIB0047|ijcp12979-cit-0047","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0048|ijcp12979-cit-0048","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2016.06.015","article-title":"Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol","volume":"251","author":"Lappeg\u00e5rd","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1111\/ijcp.12979-BIB0049|ijcp12979-cit-0049","doi-asserted-by":"crossref","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1111\/ijcp.12979-BIB0050|ijcp12979-cit-0050","unstructured":"Stein E Sampietro T Santos R Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG)"},{"key":"10.1111\/ijcp.12979-BIB0051|ijcp12979-cit-0051","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0052|ijcp12979-cit-0052","unstructured":"Bruckert E Effect of alirocumab on the frequency of lipoprotein apheresis: a randomised phase III trial"},{"key":"10.1111\/ijcp.12979-BIB0053|ijcp12979-cit-0053","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0054|ijcp12979-cit-0054","article-title":"ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia","volume":"130","author":"Ginsberg","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0055|ijcp12979-cit-0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2042098612439884","article-title":"Safety of statins: an update","volume":"3","author":"Hu","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1111\/ijcp.12979-BIB0056|ijcp12979-cit-0056","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1111\/ijcp.12979-BIB0057|ijcp12979-cit-0057","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/imj.12706","article-title":"Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis","volume":"45","author":"Luo","year":"2015","journal-title":"Intern Med J"},{"key":"10.1111\/ijcp.12979-BIB0058|ijcp12979-cit-0058","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0059|ijcp12979-cit-0059","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0735-1097(16)31866-6","article-title":"A pooled safety analysis of over 6000 patients from double-blind and open-label extension studies with evolocumab","volume":"67","author":"Toth","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0060|ijcp12979-cit-0060","unstructured":"US Food and Drug Administration FDA expands advice on statin risk 2014 http:\/\/www.fda.gov\/ForConsumers\/ConsumerUpdates\/ucm293330.htm"},{"key":"10.1111\/ijcp.12979-BIB0061|ijcp12979-cit-0061","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1715163515578692","article-title":"Statins and their effect on cognition: let's clear up the confusion","volume":"148","author":"Gauthier","year":"2015","journal-title":"Can Pharm J (Ott)"},{"key":"10.1111\/ijcp.12979-BIB0062|ijcp12979-cit-0062","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Saf"},{"key":"10.1111\/ijcp.12979-BIB0063|ijcp12979-cit-0063","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0064|ijcp12979-cit-0064","doi-asserted-by":"crossref","first-page":"Jc31","DOI":"10.7326\/ACPJC-2016-164-6-031","article-title":"Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia","volume":"164","author":"Santos","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12979-BIB0065|ijcp12979-cit-0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2016.02.011","article-title":"Role of PCSK9 antibodies in cardiovascular disease: critical considerations of mortality and neurocognitive findings from the current literature","volume":"247","author":"Kolodziejczak","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1111\/ijcp.12979-BIB0066|ijcp12979-cit-0066","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jcph.832","article-title":"Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment","volume":"57","author":"Gibbs","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/ijcp.12979-BIB0067|ijcp12979-cit-0067","first-page":"343","article-title":"Pharmacokinetics and pharmacodynamics of evolocumab in patients with renal impairment","volume":"37","author":"Lee","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12979-BIB0068|ijcp12979-cit-0068","first-page":"A16850","article-title":"Abstract 16850: Effect of alirocumab in patients with diabetic dyslipidemia and chronic kidney disease","volume":"134","author":"Dwyer","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0069|ijcp12979-cit-0069","first-page":"A16865","article-title":"Safety and tolerability of very low LDL-C levels in patients treated with 52\u00a0weeks of evolocumab (AMG 145)","volume":"130","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0070|ijcp12979-cit-0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0071|ijcp12979-cit-0071","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better - LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12979-BIB0072|ijcp12979-cit-0072","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrcardio.2015.208","article-title":"Dyslipidaemia in 2015: advances in treatment of dyslipidaemia","volume":"13","author":"Grundy","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/ijcp.12979-BIB0073|ijcp12979-cit-0073","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/expphysiol.2006.035147","article-title":"Human cholesterol metabolism and therapeutic molecules","volume":"93","author":"Charlton-Menys","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1111\/ijcp.12979-BIB0074|ijcp12979-cit-0074","unstructured":"ClinicalTrials.gov REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01252953"},{"key":"10.1111\/ijcp.12979-BIB0075|ijcp12979-cit-0075","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12979-BIB0076|ijcp12979-cit-0076","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40256-016-0179-y","article-title":"LDL-cholesterol: standards of treatment 2016 - a German perspective","volume":"16","author":"M\u00e4rz","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1111\/ijcp.12979-BIB0077|ijcp12979-cit-0077","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/ijcp.12979-BIB0078|ijcp12979-cit-0078","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12979-BIB0079|ijcp12979-cit-0079","first-page":"A68","article-title":"Efficacy and safety of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes","volume":"64","author":"Sattar","year":"2015","journal-title":"Diabetes"},{"key":"10.1111\/ijcp.12979-BIB0080|ijcp12979-cit-0080","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12979-BIB0081|ijcp12979-cit-0081","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150\u00a0mg every 4\u00a0weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.12979\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T15:20:52Z","timestamp":1659280852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12979","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}